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ABSTRACT TheinitiationofhyperinvasivediseaseingroupA Streptococcus(GAS)serotypeM1T1occursbymutationwithinthe
covRStwo-componentregulon(named covRSforcontrolofvirulenceregulatorysensorkinase),whichpromotesresistanceto
neutrophil-mediatedkillingthroughtheupregulationofbacteriophage-encodedSda1DNase.Todeterminewhetherotherviru-
lencefactorscontributetothisphase-switchingphenomenon,westudiedapanelof10isogenicGASserotypeM1T1virulence
gene knockout mutants. While loss of several individual virulence factors did not prevent GAS covRS switching in vivo, we found
thatM1proteinandhyaluronicacidcapsuleareindispensablefortheswitchingphenotype,aphenomenonpreviouslyattributed
uniquelytotheSda1DNase.WedemonstratethatlikeM1proteinandSda1,capsuleexpressionenhancessurvivalofGASsero-
typeM1T1withinneutrophilextracellulartraps.Furthermore,capsuleshareswithM1proteinaroleinGASresistancetohuman
cathelicidinantimicrobialpeptideLL-37.WeconcludethataquorumofGASserotypeM1T1virulencegeneswithcooperative
roles in resistance to neutrophil extracellular killing is essential for the switch to a hyperinvasive phenotype in vivo.
IMPORTANCE ThepathogengroupAStreptococcus(GAS)causesawiderangeofhumaninfectionsrangingfromthesuperﬁcial
“strepthroat”topotentiallylife-threateningconditions,suchasnecrotizingfasciitis,alsoknownas“ﬂesh-eatingdisease.”A
markedincreaseinthenumberofcasesofsevereinvasiveGASinfectionduringthelast30yearshasbeentracedtotheemer-
genceandspreadofasinglecloneoftheM1T1serotype.RecentstudieshaveshownthatGASserotypeM1T1bacteriaundergoa
genetic “switch” in vivo to a hypervirulent state that allows dissemination into the bloodstream. The present study was under-
takentoidentifyspeciﬁcGASserotypeM1T1virulencefactorsrequiredforthisswitchtohypervirulence.Thesurface-anchored
GASM1proteinandhyaluronicacidcapsulearefoundtobeessentialfortheswitchingphenotype,andanovelroleforcapsule
inGASresistancetohostdefensepeptidesandneutrophilextracellularkillingisrevealed.
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S
treptococcus pyogenes (group A Streptococcus [GAS]) is an im-
portant bacterial pathogen responsible for numerous human
diseases, ranging from benign skin infections, such as impetigo
andpharyngitis,tolife-threateninginvasiveconditions,including
necrotizingfasciitisandtoxicshocksyndrome(1,2).Theglobally
disseminated GAS serotype M1T1 clone is chieﬂy responsible for
the resurgence of severe invasive disease caused by GAS over the
past 3 decades (3). Recent evidence indicates that invasive disease
caused by serotype M1T1 GAS is instigated by spontaneous mu-
tationofthecovRStwo-componentregulator(4–6),whichresults
in the upregulation of several virulence factors, including a
bacteriophage-encoded DNase designated Sda1 (5). High-level
expression of Sda1 facilitates the degradation of DNA neutrophil
extracellular traps (NETs), thereby promoting GAS resistance to
neutrophil-mediated killing at the initial site of infection (7, 8).
Concomitantly, covRS mutation blocks expression of streptococ-
cal pyrogenic exotoxin B (SpeB), a broad-spectrum GAS cysteine
protease(5,9),therebypreservingtheintegrityofSda1andseveral
additional GAS virulence proteins (10). SpeB inactivation allows
streptokinase,M1protein,andhostplasminogentoremainintact
atthesiteofinfection,leadingtoaccumulationofplasminactivity
on the bacterial cell surface and facilitating systemic spread (11).
Targeted deletion of sda1 abolishes selection for covRS muta-
tion in vivo following subcutaneous mouse infection, identifying
Sda1asapivotalfactorininvasivediseasecausedbyGASserotype
M1T1 (6). This ﬁnding suggests that selective pressure exerted by
neutrophils, and in particular NETs, during local infection favors
accumulation of SpeB-negative covRS mutants within the GAS
serotype M1T1 population, thereby enhancing the propensity for
severe invasive disease (6). The objective of the current investiga-
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factors, each found to contribute to neutrophil resistance and/or
diseaseinsmallanimalmodels,werethemselvesessentialcontrib-
utorstotheM1T1switchtohypervirulence.Apanelof10isogenic
mutants harboring precise virulence gene mutations were sur-
veyed for SpeB expression status following in vivo selection. After
surveying these 10 mutants, we report that two GAS virulence
determinants, M1 protein and hyaluronic acid capsule, are essen-
tial for the in vivo selection of covRS mutations, whereas the indi-
vidualdeletionofseveralothervirulencefactorsdidnotinﬂuence
this propensity. Furthermore, we demonstrate that hyaluronic
acid capsule, like the Sda1 DNase and M1 protein (12), mediates
resistance to bacterial clearance within NETs, likely through inhi-
bition of cathelicidin antimicrobial peptides. These data suggest
that a speciﬁc coordinated subset of GAS serotype M1T1 neutro-
phil survival factors is required for in vivo phase-switching and
hypervirulence.
RESULTS
Effect of virulence gene deletion on GAS serotype M1T1 in vivo
phase-switching. To assess the in vivo phase-switch of SpeB
duringinfection,miceweresubcutaneouslyinfectedwithnon-
lethaldosesofwild-type(WT)GASserotypeM1T1strain5448
andapanelof10isogenicvirulencegenemutantsderivedfrom
thisstrain.Thebacteriaintheinoculawerecountedtoconﬁrm
that equivalent doses were administered for all strains
(Fig.1A).TheWTandmutantinoculawereuniformlypositive
for SpeB proteolytic activity (50 colonies), with the exception
of the 5448speB negative control (Fig. 1B). At 72 h postinfec-
tion, bacterial counts within the skin lesions were comparable
for WT and mutant strains (Fig. 1C). For each bacterial strain,
50 colonies derived from the lesions of 10 separate mice (500
total)werescreenedforlossofSpeBactivityindicativeofcovRS
mutation. GAS serotype M1T1 mutants lacking streptolysin O
(5448slo) (13), streptolysin S (5448sagA) (14), pilus T1 an-
tigen (5448pili) (15), interleukin 8 (IL-8) protease SpyCEP
(5448cepA) (16), NAD glycohydrolase (5448nga) (13),
D-alanylation of teichoic acids (5448dltA) (17), and large
surface-anchored(Lsa)antigen(5448lsa)(18)(alsoknownas
extracellularproteinfactor[Epf])alldemonstratedaclearabil-
ity to switch to the SpeB-negative covRS mutant phenotype in
vivo, albeit with somewhat differing efﬁciencies compared to
the WT (Fig. 1D). In contrast, phase-switching associated with
loss of SpeB expression in vivo was completely abrogated in
isogenic GAS mutants lacking M1 protein (5448emm1)o r
hyaluronicacidcapsule(5448hasA)(Fig.1D).Uponcomple-
FIG1 M protein and hyaluronic acid capsule are indispensable for in vivo selection of the covRS mutant phenotype in GAS serotype M1T1. (A) Quantiﬁcation
of nonlethal inoculum administered to mice subcutaneously. Each symbol shows the value for an individual mouse. The short horizontal bar denotes the
arithmeticmean.(B)PercentageofWTandisogenicmutantcoloniesnegativeforSpeBproteaseactivityintheoriginalinoculum(n50).(C)Bacterialloadper
gram/tissueinharvestedskinlesions(n10)3daysaftersubcutaneousinfection.(D)PercentageofSpeB-negativecoloniesinskinlesionafter72h(10miceper
strain and 50 colonies tested per animal). Each symbol shows the value for an individual mouse. The short horizontal bar denotes the arithmetic mean for each
group or strain.
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pressing M1 protein (pM1) or restoration of the hasA allele
within a plasmid excisional revertant of mutant strain
5448hasA (5448hasA.R1), the capacity of each mutant to
switch to a SpeB-negative phenotype was restored (Fig. 1D).
DNAsequenceanalysisofseveralSpeB-negativelesion-derived
colonies identiﬁed mutations within the covRS locus (Table 1),
consistent with previous studies (5, 6, 9). These data indicate
an essential role for M protein and capsule in GAS serotype
M1T1 in vivo phase-switching, analogous to that previously
identiﬁed for the Sda1 DNase (6).
Neutrophil survival. The Sda1 DNase contributes to GAS vir-
ulence by degrading NETs, thus allowing the pathogen to escape
neutrophil extracellular killing (7, 8). Recently, we demonstrated
thatM1proteinstimulatesNETformationyetalsopromotesGAS
serotype M1T1 bacterial survival within these DNA-based innate
defensestructuresbyconferringresistancetocathelicidinantimi-
crobial peptides (12). To pursue this linkage, we examined how
the hyaluronic acid capsule, the third identiﬁed contributor to
covRSphase-switchinginvivo,contributedtoGASserotypeM1T1
neutrophil and NET resistance. Enzyme-linked immunosorbent
assay (ELISA) results demonstrated that hyaluronic acid was ab-
sent in the 5448hasA mutant and restored to the WT level in the
5448hasA.R1 revertant strain (Fig. 2A). Compared to the WT
parentandrevertantstrains,theacapsular5448hasAmutantwas
more sensitive to total neutrophil-mediated killing (Fig. 2B). To
isolateextracellularneutrophilkilling,theassayswererepeatedin
the presence of cytochalasin D, an actin cytoskeleton inhibitor
that blocks phagocytosis. As an assay control, extracellular killing
of strain 5448AP (Fig. 2C), the SpeB-negative covS mutant that
expresses high levels of the NET-degrading Sda1 DNase (6), was
greatly diminished. We found that the acapsular 5448hasA mu-
tant exhibited a small but signiﬁcant reduction in survival com-
pared to the WT and revertant strains (Fig. 2C), indicating that
hyaluronic acid capsule expression contributes to GAS resistance
toextracellularneutrophilkilling,aphenomenongenerallyattrib-
utable to entrapment and/or killing within NETs (19, 20).
NET induction and entrapment. In contrast to M1 protein,
which is necessary and sufﬁcient to promote the induction of
NETs (12), no signiﬁcant differences were found in the levels of
NETs induced by the WT, hyaluronic acid capsule mutant, or
revertant strains (Fig. 3A). Similarly, the absence of capsule did
not affect bacterial entrapment within DNA NETs (Fig. 3B). To-
gether these data show that GAS serotype M1T1 capsule does not
enhance neutrophil survival by reducing NET induction or en-
trapment within these structures.
Survival within NETs and cathelicidin resistance. Immuno-
ﬂuorescence microscopy of NET-entrapped GAS using the Live/
Dead BacLight bacterial viability kit revealed a markedly higher
proportion of dead cells for the acapsular
5448hasA mutant compared to either
the WT parent strain or revertant strain
5448hasA.R1 (Fig. 4A). These ﬁndings
indicate that as found for the M1 protein
(12), hyaluronic acid capsule contributes
to GAS serotype M1T1 survival within
NETs. Cathelicidin antimicrobial pep-
tides are important effectors of bacterial
killing within NETs (20, 21), and inhibi-
tion of human cathelicidin LL-37 is a key
factor by which M1 protein promotes
NET resistance (12). We found that the
MIC of LL-37 for the 5448hasA mutant
was 2-fold lower than that calculated for
the WT or revertant strains in both loga-
rithmic and stationary growth phases
(Fig. 4B). The enhanced susceptibility to
LL-37ofthe5448hasAmutantwascon-
ﬁrmed in kinetic killing assays (Fig. 4C).
FIG 2 Capsule promotes resistance to neutrophil-mediated killing of GAS serotype M1T1. (A) Cap-
sular hyaluronic acid quantiﬁcation. Values denote arithmetic means plus standard errors (SEs) (error
bars) and are representative of two independent experiments performed in triplicate. (B) Bacterial
survival in total (intracellular plus extracellular) neutrophil killing assays. Values represent arithmetic
means plus SEs and are representative of three independent experiments performed in triplicate. (C)
Survivalinextracellularneutrophilkillingassayswhenphagocyticuptakeisinhibitedwithcytochalasin
D (10 g/ml). Values denote arithmetic means plus SEs and are representative of three independent
experiments performed in triplicate. Values that are statistically signiﬁcantly different (P  0.05) from
the value for isolate 5448 (wild type [WT]) are indicated by an asterisk.
TABLE 1 DNA sequence analyses of mutations within covRS genesa
GAS strain Mouse ID no.b Mutationc
5448 1 G-to-T mutation at nt 1441 in covS
5448 2 A insertion at nt 803 in covS
5448cepA 1 C-to-T mutation at nt 1363 in covS
5448cepA 2 T-to-C mutation at nt 866 in covS
5448dltA 1 A-to-G mutation at nt 278 in covR
5448dltA 2 C-to-T mutation at nt 889 in covS
5448nga 1 AAAGG insertion at nt 867 in covS
5448nga 2 TTTTTT insertion at nt 76 in covS
C insertion at nt 77 in covS
GCA insertion at nt 78 in covS
C insertion at nt 82 in covS
5448pili 1 C-to-T mutation at nt 1003 in covS
5448pili 2 TTTTTT insertion at nt 76 in covS
C insertion at nt 77 in covS
GCA insertion at nt 78 in covS
C insertion at nt 82 in covS
5448slo 1 T insertion at nt 1409 in covS
5448slo 2 T deletion at nt 213 in covS
5448lsa 1 G-to-A mutation at nt 1189 in covS
5448lsa 2 C insertion at nt 137 in covS
5448sagA 1 C-to-T mutation at nt 761 in covS
5448sagA 2 C-to-T mutation at nt 761 in covS
5448emm1 pM1 1 C-to-T mutation at nt 352 in covR
5448emm1 pM1 2 C-to-A mutation at nt 608 in covS
5448hasA.R1 1 G insertion at nt 1374 in covS
5448hasA.R1 2 G insertion at nt 1374 in covS
a GAS serotype M1T1 strain 5448 colonies that were derived from lesions and SpeB-
negative isogenic colonies isolated 3 days after subcutaneous infection of C57BL/6J
mice with nonlethal challenge doses.
b Mouse identiﬁcation (ID) number.
c Mutation positions are based upon the nucleotide (nt) position in the covR or covS
gene relative to each ATG start codon.
M Protein and Capsule Select GAS covRS Mutants
September/October 2010 Volume 1 Issue 4 e00191-10 mbio.asm.org 3Thus, hyaluronic acid expression promotes GAS serotype M1T1
cathelicidin resistance and NET survival, which may account for
its essential role in promoting the covRS phase-switching muta-
tion to hypervirulence in this globally disseminated epidemic
strain.
DISCUSSION
The switch to a hyperinvasive GAS serotype M1T1 phenotype in
vivo occurs by mutation within covRS, which acts to shut off cys-
teineproteaseSpeBproductionwhileupregulatingtheexpression
of several other known GAS virulence factors, including hyal-
uronic acid capsule, streptolysin O (SLO), NAD glycohydrolase,
SpyCEP, and the Sda1 DNase (5). Previously, we reported that
expression of the bacteriophage-encoded Sda1, which promotes
GAS neutrophil resistance by degradation of NETs (7, 8), was
required for the covRS switching phenotype (6). Mutations in
covRSwerenotdetectedwhenthesda1mutantwasusedtochal-
lengemicesubcutaneously,andanancestralM1GASstrain,lack-
ingthephageM1T1ZencodingSda1,alsofailedtoswitchinvivo
(6). Here, we examined whether the loss of any other individual
GASvirulencefactorswouldbesufﬁcient,inandofitself,toblock
the selective pressure favoring the covRS switching phenomenon
in vivo. From a panel of 10 isogenic mutants tested, we found that
only hyaluronic acid capsule and M1 protein shared with Sda1 an
essentiality for the covRS switching phenotype.
For a number of GAS serotype M1T1 virulence factors with
established or proposed roles in resistance to neutrophil killing,
targeteddeletionofthegeneencodingthevirulencefactordidnot
eliminatecovRSswitchinginvivo.TheSpyCEPpeptidasedegrades
thekeyhumanCXCchemokine(chemokinewiththeC-X-Cmo-
tif) IL-8 to impair directed neutrophil migration and bacterial
killing(16,22),yetcovRSswitchingoftheGAScepAmutantwas
still readily detected. GAS promotes the accelerated cell death of
neutrophils and macrophages through the action of its pore-
forming toxins streptolysin S (SLS) and streptolysin O (SLO) (13,
14, 23, 24), but loss of either toxin did not eliminate the covRS
switching propensity. Likewise, deletion of the surface-anchored
protein Lsa (aka Epf) (18, 25), the largest protein encoded by a
gene in the serotype M1T1 genome, pilus subunit Spy1028 (15),
thebuildingblockfortherecentlydiscoveredﬁbrillarGASsurface
appendages (26), or the NAD glycohydrolase which enhances
GAS cytotoxicity through depletion of host intracellular energy
stores (27, 28), did not eliminate covRS switching. The data indi-
cate that a GAS strain lacking any one of these components nev-
ertheless will experience enhanced survival at the site of infection
through covRS mutation, such that the selective pressure favoring
the in vivo mutation for the WT parent strain is retained.
GAS lacking M1 protein (emm1) did not undergo detectable
levels of covRS mutation in vivo. The speciﬁcity of this phenome-
FIG3 HyaluronicacidcapsuleexpressiondoesnotsigniﬁcantlyinﬂuenceGASinductionof,norentrapmentwithin,neutrophilextracellulartraps(NETs).(A)
DAPI-stained DNA NETs (blue) induced by WT GAS serotype M1T1 strain 5448, capsule-deﬁcient mutant 5448hasA, and revertant 5448hasA.R1. Fluores-
cent images are representative of three independent experiments. The bar graph shows quantiﬁcation of DNA NET induction per ﬁeld of view after exposure to
Sytox Orange. Values denote arithmetic means plus SEs (error bars) and are representative of three independent experiments performed in triplicate. (B)
Entrapment of FITC-labeled bacteria (green) within DAPI-stained DNA NETs (blue) for WT GAS serotype M1T1 strain 5448, capsule-deﬁcient mutant
5448hasA, and revertant 5448hasA.R1. Fluorescent images are representative of three independent experiments. The bar graph shows quantiﬁcation of
FITC-labeled GAS trapped within DNA NETs by spectroﬂuorometry. Values denote arithmetic means plus SEs and are representative of two independent
experiments performed in triplicate.
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restored when the emm1 mutant was complemented using a
plasmidexpressingM1protein.GASMproteinsareamultifacto-
rial surface-associated GAS virulence factor that interferes with
neutrophil opsonophagocytosis through the binding of ﬁbrino-
gen(29),complementinhibitoryfactorH(30),C4b-bindingpro-
tein (31), and immunoglobulin Fc regions (31). GAS M1 protein
has also been shown to promote GAS survival within neutrophils
byinhibitingazurophilicgranulefusionwiththephagosome(32).
Recently, M1 protein was found to stimulate the production of
NETsbutpromotedGASsurvivalwithinthesehostdefensestruc-
tures, perhaps by increasing GAS resistance to cathelicidin anti-
microbial peptides deployed within the NETs (12). Enhanced re-
sistance to NET-based killing is a phenotypic property shared by
M1proteinandtheSda1DNase(6,7),andwenowrecognizethat
both virulence factors are required for the GAS covRS switching
phenotype in vivo. While transcription of the emm1 gene is not
signiﬁcantly upregulated upon covRS mutation as is transcription
of the sda1 gene (5), M1 protein is normally cleaved/degraded by
theSpeBproteasewhoseexpressionisshutoffbythecovRSswitch
mechanism (10, 33). Thus, sparing M1 protein from SpeB cleav-
age results in enhanced neutrophil resistance, leading to selection
of covRS mutants with abolished SpeB expression in vivo.
The hyaluronic acid capsule is a linear high-molecular-weight
polymerofglucuronic--1,3-N-acetylglucosaminelocatedonthe
surfaces of all GAS strains. The capsule, which is encoded by the
highly conserved has synthase operon (34), is essentially identical
to mammalian polysaccharides, and this molecular mimicry en-
ables GAS to avoid detection by the host immune system (2).
Acapsular GAS mutants are sensitive to phagocytic killing in vitro
and have reduced virulence in a murine model of invasive infec-
tioncomparedwiththeencapsulatedWTstrain(35,36).Here,we
ﬁnd that GAS serotype M1T1 capsule-deﬁcient bacteria do not
undergo covRS switching in vivo, but a revertant regains this ca-
pacity. Since we have correlated the absence of covRS switching in
sda1 and emm1 mutants with a role in NET resistance for the
genes encoding virulence factors, we examined for the ﬁrst time
whether GAS hyaluronic acid capsule contributes to extracellular
neutrophil resistance. In contrast to ﬁndings with M1 protein
(12), GAS capsule did not contribute to NET induction, and in
contrast to studies of the pneumococcal polysaccharide capsule
(37), GAS capsule did not impair NET entrapment. However,
similar to our observations with M1 protein (12), we found that
GAScapsulepromotedbacterialsurvivalwithinhumanNETsand
thatthisphenotypecouldbecorrelatedtoresistancetothehuman
cathelicidinantimicrobialpeptideLL-37,amajorcomponentand
FIG 4 Capsule enhances GAS serotype M1T1 survival within extracellular traps and resistance to human cathelicidin LL-37. (A) Immunoﬂuorescence
microscopicoverlayimagesofviablebacteria(green)versusdeadbacteria(red)entrappedwithinDAPI-stainedNETs(blue)forWTGASserotypeM1T1strain
5448, capsule-deﬁcient mutant strain 5448hasA, and revertant strain 5448hasA.R1. Fluorescent images are representative of three independent experiments.
(B) MICs for cathelicidin antimicrobial peptide LL-37 against WT GAS serotype M1T1 strain 5448, capsule-deﬁcient mutant 5448hasA, and revertant
5448hasA.R1 in logarithmic and stationary growth phases. (C) Killing kinetics for WT GAS serotype M1T1 strain 5448, capsule-deﬁcient mutant 5448hasA,
andrevertant5448hasA.R1inthepresenceofLL-37(64M).ThegrowthindexwascalculatedasthenumberofCFUatthespeciﬁedtimepoint/numberofCFU
intheinitialinoculum.ValuesdenotearithmeticmeansSEs(errorbars)andarerepresentativeoftwoindependentexperimentsperformedintriplicate.Values
that are statistically signiﬁcantly different (P  0.05) from the value for strain 5448 are indicated by an asterisk.
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LL-37 has been reported to lead to covRS-mediated upregulation
ofcapsuleexpression(38);thus,ourdiscoveryofaroleforcapsule
in cathelicidin resistance is consistent with a speciﬁc adaptive
function of this sensing mechanism. Recently, trapping of other
hostdefensepeptides,suchashumanneutrophilalpha-defensin1
(HNP-1), beta-defensin 1, and lactoferrin before they can reach
their cell wall target of action has been proposed as an immune
resistancemechanismforcapsularpolysaccharidesofhumanbac-
terial pathogens, including Klebsiella pneumoniae, Streptococcus
pneumoniae, and Pseudomonas aeruginosa (39, 40).
We found that both M1 protein and capsule promote resis-
tance to human cathelicidin LL-37, which may be an important
contributor to the NET resistance phenotype. However, we show
in the present study that the GAS dltA mutant, which exhibits
increased anionic surface charge and increased susceptibility to
cationic antimicrobial peptides, including cathelicidin (17), still
underwentcovRSswitchinginvivo.Ofnote,comparedtothepar-
ent strain, a Staphylococcus aureus dltA mutant was recently
shown to have enhanced sensitivity to cathelicidin within the
phagolysosome but not to cathelicidin within NETs (41). This
suggests that sequestration of cathelicidin (by M1 protein and
perhaps hyaluronic acid capsule) may be a more effective pheno-
type for cathelicidin resistance than charge repulsion within the
NET environment.
In sum, our data indicate that the Sda1 nuclease, M1 protein,
and hyaluronic acid capsule comprise a quorum of cooperative
virulencefactorsthatpromoteresistancetoNETkillingatthesite
ofinfectionandthatefﬁcientNETresistanceisrequiredforinvivo
selectionofthecovRSphenotypelinkedtohypervirulenceandthe
initiation of invasive disease caused by GAS M1T1 serotype. A
number of other bona ﬁde GAS virulence factors, while inﬂuenc-
ing neutrophil resistance and/or virulence in the murine model,
do not appear to alter the fundamental covRS switching pheno-
typesigniﬁcantly.Thisinformationsuggestsacertainhierarchyof
virulence determinants with respect to this sentinel event in GAS
serotype M1T1 disease progression.
MATERIALS AND METHODS
Bacterial strains, media, and culture conditions. Human GAS serotype
M1T1 isolate 5448 was isolated from a patient with necrotizing fasciitis
and toxic shock (9). The isogenic animal-passaged SpeB-negative variant
5448AP has been described previously (10). The isogenic in-frame allelic
exchange knockout mutants 5448cepA (16), 5448dltA (17), 5448nga
(13), 5448emm1 (12), 5448slo (13), 5448lsa (18), 5448speB (10),
5448sagA (14), and 5448pili (15) have been described previously. The
integrational mutant 5448hasA was constructed by Hollands et al. (42).
Plasmid-based complementation of the 5448emm1 mutant strain with
pDCerm-emm1,hereafterdesignated5448emm1pM1,isdescribedelse-
where (12). All GAS strains were routinely propagated at 37°C on Todd-
Hewitt agar (THA) (Difco) or in static liquid cultures of Todd-Hewitt
broth (THB). Where appropriate, strains were grown in media supple-
mented with 2 g/ml erythromycin (Em).
DNAtechniques.ChromosomalDNAwasextractedusingtheColony
Fast-Screen kit (Epicentre Biotechnologies). PCR was performed under
standard conditions using Platinum Blue PCR supermix (Invitrogen), in
accordance with the manufacturer’s recommendations.
IntegrationalmutagenesisofhasA.ThehasAgeneinGASstrain5448
was insertionally inactivated as previously described (42), using
temperature-sensitiveEmrvectorpHY304.Attemptsatcomplementation
of the hasA gene or the entire has operon of the 5448hasA mutant with
multicopy plasmid vector pDCerm yielded slow-growing transformants,
suggesting toxicity associated with gene overexpression (not shown).
Thus, to generate a revertant to the wild-type (WT) phenotype, hence-
forth designated 5448hasA.R1, the Emr 5448hasA mutant strain was
passaged at 30°C for 2 days in THB without antibiotic selection pressure,
prior to plating serial dilutions onto THA and overnight incubation at
37°C. Loss of the integrated plasmid from the mutant 5448hasA
chromosome was identiﬁed by screening single colonies for Ems phe-
notype.RestorationofthehasAallelewasconﬁrmedbythehyaluronic
acid capsule assay and by PCR using primer pair HasA-F (5=-
AATGTTTCCTTAATAAATAGTGTG-3=) and HasA-R (5=-
AAAATTACTCCTTCTCTAACT-3=).
Hyaluronic acid capsule assay. Capsular hyaluronic acid levels were
quantiﬁedbythemethodofHollandsetal.(42),usingthehyaluronicacid
quantitative test kit (Corgenix), in accordance with the manufacturer’s
directions.
FITClabelingofbacteria.GASbacteriawerelabeledwithﬂuorescein
isothiocyanate(FITC)byamodiﬁedversionofthemethodofGoldmann
et al. (43). Overnight GAS cultures diluted 1:10 into fresh THB were
growntomid-logarithmicphase,centrifugedat3,220gfor10min,and
thenresuspendedinphosphate-bufferedsaline(PBS)toanopticaldensity
at 600 nm (OD600) of 0.4, corresponding to ~2  108 CFU/ml. Bacteria
wereincubatedinthepresenceof0.2mg/mlFITCfor30minoniceinthe
dark, centrifuged at 3,220  g for 10 min, washed twice with PBS to
remove excess FITC, and resuspended to the original volume in RPMI
1640 medium without phenol red (Invitrogen) but with 2% heat-
inactivated human plasma.
Subcutaneous infection. Overnight cultures of GAS diluted 1:10 to a
ﬁnalvolumeof10mlinTHBweregrowntoanOD600of0.4,correspond-
ing to mid-logarithmic phase and ~2  108 CFU/ml. Following centrifu-
gation at 3,220  g for 15 min, bacterial pellets were washed twice with
10 ml PBS and resuspended in a ﬁnal volume of 1 ml PBS. Separate co-
horts (n  10) of 8-week-old female C57BL/6J mice (Charles River Lab-
oratories,Wilmington,MA)weresubcutaneouslyinoculatedwithanon-
lethal dose (~108 CFU/100 l) to examine the in vivo phase-switch of
SpeB during infection. To calculate the precise dose administered, serial
dilutionsofinoculawereplatedontoTHA,andthebacteriawereenumer-
atedfollowingovernightincubationat37°C.Singlecolonies(50perinoc-
ulum) were tested for SpeB proteolytic activity.
Skin lesion harvest and processing. Three days postinfection, mice
were euthanized by CO2 asphyxiation, and excised skin lesions were
placedintosterilepreweighed2-mlscrew-capmicrotubescontaining1ml
sterile PBS and 1-mm zirconia/silica beads (BioSpec Products). After the
tubeswereweighedtodeterminelesionmass,bacteriawerereleasedfrom
the skin using two 1-min homogenization bursts with a Mini-BeadBeater
(BioSpec Products), in accordance with the manufacturer’s instructions.
Homogenates were placed on ice for 1 min between bursts to prevent
overheating. To quantify bacterial load, homogenates were 10-fold seri-
ally diluted in PBS, plated onto THA, and counted following overnight
incubation at 37°C. Individual lesion-derived colonies (n  50) were as-
sayed for SpeB expression status.
Cysteineproteaseactivityassay.SpeBproteaseactivityinstationary-
phaseGASculturesupernatantswasdeterminedusingtheazocaseinolytic
assay (44) modiﬁed for the 96-well plate format. Single colonies were
inoculatedintowells(eachwellcontaining200lTHB)andincubatedat
37°C overnight. After the culture was mixed, 20 l of the culture was
subinoculated into 180 l fresh THB and incubated at 37°C overnight.
The cultures were mixed, and the plates were centrifuged at 3,220  g for
10minatroomtemperature.Fortymicrolitersofculturesupernatantand
40 l of activation buffer (0.1 M sodium acetate [NaAc] [pH 5], 1 mM
EDTA, 20 mM dithiothreitol [DTT]) were mixed in the wells of a fresh
microtiter plate and incubated for1ha t40°C. Following the addition of
80 l of 2% azocasein in activation buffer, the plates were placed at 40°C
for1h.SpeB-positivewellswereidentiﬁedvisuallybytheorangeturbidity
generatedbyazocaseinlysisincomparisontotheTHB-onlycontrol.Col-
onies were scored SpeB negative following negative results in consecutive
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supernatantswereincludedaspositiveandnegativecontrols,respectively.
covRSsequenceanalysis.SpeB-negativelesion-derivedcolonieswere
screened for mutations within the covRS locus essentially as previously
described (6).
Neutrophil killing assays. Human neutrophils were isolated and
puriﬁed from venous blood using the Polymorphprep system (Axis-
Shield), resuspended in RPMI 1640 medium (Invitrogen) containing
2% autologous heat-inactivated human plasma, and seeded into 96-
well plates at 2  105 cells/well. GAS bacteria grown to logarithmic
phase(OD600of0.4)inTHBweredilutedtothedesiredconcentration
in RPMI 1640 medium plus 2% heat-inactivated human plasma and
then added to neutrophils at a multiplicity of infection of 1:10 (GAS-
to-neutrophilratio).Theplateswerecentrifugedat500 g for10min
andincubatedat37°Cin5%CO2 for30min.Thecontentsofthewells
were serially diluted in sterile H2O for neutrophil lysis and then plated
on THA for overnight incubation and enumeration of surviving GAS
CFU. Internal control wells without neutrophils were used to deter-
mine baseline bacterial counts at the assay endpoints. Percent survival
of GAS was calculated as [(CFU/ml experimental well)/(CFU/ml con-
trol well)]  100. For extracellular killing assays, neutrophils were
treated with 10 g/ml cytochalasin D (Sigma-Aldrich) to inhibit
phagocytosis 10 min prior to infection.
Immunoﬂuorescence assays. Extracellular trap visualization and
viability of GAS entrapped within NETs was undertaken using the
Live/Dead BacLight bacterial viability and counting kit (Invitrogen)
per the manufacturer’s directions. Glass coverslips (1.5 oz, 12 mm;
Fisher) were placed in 24-well ultralow-attachment cluster plates
(Costar) and coated with 100 l of 0.01% poly-L-lysine (Sigma). After
10-min incubation at room temperature, the wells were washed twice
with PBS and seeded with 5  105 human neutrophils in 500 lo f
RPMI 1640 medium plus 2% heat-inactivated human plasma. The
cells were infected with logarithmic-phase GAS at a multiplicity of
infection of 2:1 (GAS-to-neutrophil ratio), centrifuged at 500  g for
10 min, and incubated for 20 min at 37°C in the presence of 5% CO2.
ThecellswerewashedtwicewithPBSpriortotheadditionof200lof
dye and incubation in the dark for 15 min at room temperature. Fol-
lowing three PBS washes, cells were ﬁxed by the addition of parafor-
maldehyde (PFA) to a ﬁnal concentration of 1% for 5 min and then
washed three times with PBS before the coverslips were embedded on
microscope slides in 5 l of ProLong Gold antifade reagent with 4=,6-
diamidino-2-phenylindole (DAPI) (Invitrogen). The slides were
stored at 4°C in the dark prior to NET visualization using an inverted
confocal laser-scanning 2-photon microscope Olympus FluoView
FV1000 with FluoView spectral scanning technology (Olympus). Im-
ages were obtained using 20/0.7 or 60/1.42 PlanApo objectives.
QuantiﬁcationofNETs.HumanneutrophilsweremixedwithGASat
a multiplicity of infection of 1:10 (GAS-to-neutrophil ratio) as described
above,andSytoxOrange(MolecularProbes)wasaddedtoaﬁnalconcen-
tration of 0.1 M. Following centrifugation at 500  g for 10 min and 5
min of incubation at 37°C in the presence of 5% CO2, extracellular traps
were visualized using a Zeiss Axiovert 100 inverted ﬂuorescence micro-
scope. Quantiﬁcation of NETs was determined by counting transects
from three independent wells.
NETentrapmentassays.FreshlyisolatedhumanneutrophilsinRPMI
1640 medium without phenol red (Invitrogen) but with 2% autologous
heat-inactivatedhumanplasmawereseededat2105perwellin96-well
platesandincubatedwith25nMphorbol12-myristate13-acetate(PMA)
f o r4ha t37°C in the presence of 5% CO2 to maximally induce NETs and
eliminate phagocytosis. An equal volume of FITC-labeled bacteria
(100 l) was added at a multiplicity of infection of 100:1 (GAS-to-
neutrophil ratio), followed by centrifugation at 500  g for 10 min and
incubation for 30 min at 37°C in the presence of 5% CO2. To remove
unboundbacteria,thewellsweregentlywashedtwicewith200lofRPMI
1640 medium without phenol red but with 2% heat-inactivated human
plasma,andtheentrappedbacteriaweremeasuredbyreadingtheabsorp-
tion/emission at 485/538 nm using a SpectraMax Gemini XS spectroﬂu-
orometer(MolecularDevices).PercententrapmentofGASwascalculated
as follows: [(A485/538 experimental well)/(A485/538 control well with-
out neutrophils)]  100. Control wells containing serial dilutions of
FITC-labeledbacteriawereusedforstandardcurveconstructionandsub-
sequent quantiﬁcation of entrapped bacteria.
LL-37 MICs and killing assays. Overnight GAS cultures were diluted
1:10 into fresh THB and grown to logarithmic phase (OD600 of 0.4). The
bacterialculturewasdiluted1:2,000inPBSplus50%THB(1105CFU/
ml), and 90-l portions were added to individual wells of a 96-well plate
containing 10 l of human cathelicidin antimicrobial peptide LL-37
(AnaSpec, San Jose, CA) serially diluted in distilled H2O, giving ﬁnal
LL-37concentrationsequalto64,32,16,8,4,and2M.Afterincubation
at 37°C for 24 h, 5 l from each well was plated onto THA and incubated
overnight. The MIC was deﬁned as the lowest concentration of LL-37
yielding inhibition of bacterial growth on THA. Killing kinetics in the
presence of LL-37 (64 M) were monitored at designated time points by
serialdilutionof25-laliquots,priortoplatingontoTHAandovernight
incubationat37°CforCFUenumeration.Growthindexwascalculatedas
follows: number of recovered CFU/number of initial CFU.
Statistical analyses. Capsular hyaluronic acid levels, neutrophil sur-
vival, NET induction and entrapment, and antimicrobial peptide resis-
tance were compared using the Student’s t test. All statistical tests were
performed using GraphPad Prism version 4.02 (GraphPad Software Inc.,
SanDiego,CA).Pvaluesof0.05wereconsideredstatisticallysigniﬁcant.
Ethics permissions. Permission to collect human blood samples and
to isolate neutrophils was approved by the University of California San
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